CLINICAL TRIALS PROFILE FOR CYTOGAM
✉ Email this page to a colleague
All Clinical Trials for CYTOGAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00203281 ↗ | Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis | Withdrawn | Sidney Kimmel Cancer Center at Thomas Jefferson University | 2003-02-01 | Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab. | |
| NCT00214240 ↗ | The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease | Completed | University of Wisconsin, Madison | N/A | 2000-01-01 | This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more effective in reducing the CMV viral load over time, as compared to standard treatment with IV ganciclovir only. Serial blood samples are drawn to measure the amount of CMV viral load weekly, while the subject is receiving treatment with ganciclovir, or ganciclovir + CytoGam®. Additional CMV viral load blood sampling (CMV DNA capture qualitative testing only) will occur weekly thereafter until the subject is 8 weeks from the time of CMV diagnosis or until the CMV infection is no longer detectable, whichever is longer duration. |
| NCT00275509 ↗ | Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch | Completed | Johns Hopkins University | Phase 3 | 2007-01-01 | The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor. |
| NCT00586716 ↗ | Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients | Terminated | Loma Linda University | N/A | 2004-11-01 | The purpose of this study is to test the clinical and laboratory observations of IVIG therapy in the highly sensitized patient. We will study the effects of patients treated with IVIG or Cytogam in combination with plasmaphoresis to modulate the immune response in highly sensitized patients. The goal is to convert a positive crossmatch to a compatible crossmatch that would allow living related transplant to take place or to shorten time on the transplant waiting list. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYTOGAM
Condition Name
Clinical Trial Locations for CYTOGAM
Trials by Country
Clinical Trial Progress for CYTOGAM
Clinical Trial Phase
Clinical Trial Sponsors for CYTOGAM
Sponsor Name
